$TWST

Cho Dennis sold $30K of TWST

Cho Dennis (See Remarks) sold 346 shares of Twist Bioscience Corp (TWST) at $87.32 on 2026-06-22.

Original reporting
SEC EDGAR · Cho Dennis
Published Jun 24, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosure updates the record of insider activity (346-share open-market sale) but does not introduce new operational or financial information about TWST.

02

Market read

Traders may monitor for insider-selling trends, but this single small sale is unlikely to drive a durable repricing without other catalysts.

03

What to watch

The article does not state motivations (taxes, diversification, planned liquidity) and provides no comparison to prior insider activity beyond the single transaction.

Relevance 3/10Novelty 3/10Timing: Form 4 filed 2026-06-24 (after-hours/late day disclosure) for a 2026-06-22 sale

Background

This is an SEC Form 4 insider transaction disclosure for Twist Bioscience (TWST).

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience officer Cho Dennis filed a Form 4 showing an open-market sale of 346 shares at $87.3224 on 2026-06-22.

Expected impact

Likely limited near-term impact; any effect should be small and short-lived unless followed by additional insider selling or new fundamentals.

Evidence & confidence

The filing is a small, non-10b5-1 sale with disclosed price and post-transaction holdings, but it does not include new company performance, guidance, or regulatory/contract events.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Insider sales are often liquidity-driven; without a pattern or accompanying 10b5-1/compensation context, the signal may be overstated.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction; officer Cho Dennis sold 346 shares at $87.3224.

  • Cho Dennis

    Officer who executed the open-market sale; holdings after transaction: 119,346 shares.

Related articles

$TWSTMedAI 8/10

Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering

Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.

$TWSTMed

Twist Bioscience Q3 Earnings Call Highlights

Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.

$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience shares (TWST) fell 4.2% in pre-open after its fiscal Q3 results missed EPS expectations. The company reported an EPS loss of $0.56 versus $0.48 expected, while revenue was $118.4M, above the $114.54M estimate. The miss follows similar EPS shortfalls in prior quarters, with mixed analyst actions noted.

$TWSTHigh

Twist Bioscience Corp (TWST): Results of Operations and Financial Condition

Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth

$AMDMedAI 8/10

Cathie Wood Pours $8. 5M Into Cerebras Amid Buzz Around AI Chip Upstart, Wont Stop Dumping AMD - Advanced

According to Benzinga, Cathie Wood’s Ark made a $10.8M purchase of Cerebras shares (42,126) on Friday, while also selling 16,998 shares of Teradyne and buying 2,451 shares of Twist Bioscience via ARKK. Separately, the report notes AMD is ramping Vera Rubin production, but U.S.-China policy and China’s share of net sales remain key factors for investors.